Amylyx selects AMX-0318 as development candidate
Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
2025 was a tumultuous year for the global healthcare sector. For much of the year, policy uncertainty, particularly around U.S. drug pricing and trade barriers, weighed heavily on valuations, which reached near 30-year lows (as mentioned by a BlackRock report). However, a dramatic shift occurred in the final quarter. The sector rebounded strongly, led by […]
THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications
THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds.
Mounjaro: Experts issue warning over black market jabs, with fifth of areas still lacking NHS access
One in five local areas in England still do not provide the weight loss jab tirzepatide (Mounjaro) on the NHS six months after the drug was supposed to be rolled out across the country, The BMJ has found.Although progress has been made since The BMJ reported that last summer less than half of England’s integrated […]
Is Giving ChatGPT Health Your Medical Records a Good Idea?
Your AI doctor’s office is expanding. On Jan. 7, OpenAI announced that over the coming weeks, it will roll out ChatGPT Health, a dedicated tab for health that allows users to upload their medical records and connect apps like Apple Health, the personalized health testing platform Function, and MyFitnessPal. According to the company, more than […]
Drug approvals to watch in 2026
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for hospital formularies, prescribing protocols and patient access. A report published Jan. 8 by GoodRx, “FDA Approval Watch: New Drugs, Vaccines, and Therapies Pending Approval in 2026” outlines several […]
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the GLP-1 and GIP receptors. VKTX is developing the candidate in both oral and subcutaneous (SC) formulations for the potential treatment of various metabolic disorders, such as obesity. Viking Therapeutics’ phase I maintenance […]
Here’s Why Biotech ETFs Are Rallying Hard
Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB rallied 36.7% in six months ending Jan. 7, 2026, outperforming SPDR S&P 500 ETF Trust SPY (up 11.2%). Year to date, IBB has risen 4.2% compared […]
Surgery Beats GLP-1 Drugs for Fat Loss, Muscle Retention, Study Suggests
(MedPage Today) — Bariatric surgery and GLP-1 receptor agonists both reduced fat mass over 2 years of treatment, but surgery was associated with a more favorable body composition, a cohort study indicated. By month 24, the covariate-adjusted…
Weight loss drugs make it harder to get the nutrients you need – here’s what to do about it
Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body already produces called glucagon-like peptide-1 (GLP-1), which helps regulate appetite and feelings of fullness. By slowing how quickly food leaves the stomach and acting on appetite centres in the brain, the drugs help people feel full […]